Tofersen, a new drug approved by the FDA for a genetic form of ALS, delays symptom progression and death and in about one-quarter of participants leads to stabilization or improvement. “Stopping disease progression and making improvements over 3 to 5 years is unheard of in this type of ALS.” 🧬💊⏳
Read Full Article
#Tofersen #ALSDisease #FDAApproval #MedicalBreakthrough #HopeForPatients
Read Full Article
#Tofersen #ALSDisease #FDAApproval #MedicalBreakthrough #HopeForPatients
WashU Medicine
New ALS drug stabilizes decline with improved strength, mobility for some | WashU Medicine
Long-term use of tofersen slows ALS disease progression in people with a genetic subtype, provides hope for treating other forms of ALS